RegisterLogin

AZD4625

CAT: 0804-HY-146223-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-146223-01Size:1 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
AZD4625 is an orally active, selective irreversible, covalent allosteric GTPase KRASG12C inhibitor with an IC50 of 3 nM. AZD4625 can inhibit the MAPK pathway (with decreased pCRAF, pMEK, and pERK) and the PI3K pathway (with decreased pAKT and pS6), and induce cell apoptosis. AZD4625 has no binding and inhibition of wild-type RAS or isoforms carrying non-KRASG12C mutations. AZD4625 can be used for the study of KRASG12C mutant non-small cell lung cancer[1][2].
UNSPSC
12352005
Target
Apoptosis; p38 MAPK; PI3K; Ras
Type
Reference compound
Related Pathways
Apoptosis; GPCR/G Protein; MAPK/ERK Pathway; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/azd4625.html
Purity
99.52
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
C=CC(N1C[C@H]2N(C3=C4C(OCC2)=C(Cl)[C@@]([C@@]5=C(F)C=CC=C5O)=C(F)C4=NC=N3)C[C@H]1C)=O
Molecular Formula
C24H21ClF2N4O3
Molecular Weight
486.90
References & Citations
[1]Kettle JG, et al. Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRASG12C. J Med Chem. 2022 May 12;65 (9) :6940-6952.|[2]Chakraborty A, et al. AZD4625 is a Potent and Selective Inhibitor of KRASG12C. Mol Cancer Ther. 2022 Oct 7;21 (10) :1535-1546.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
K-Ras

Related Products

CatalogName
HY-113938-01AZD4694
HY-111052-01AZD7325
HY-103672-01AZD7624
HY-112416-01AZD4320
HY-113820AZD4619
HY-148087-01AZD5462
HY-139516-01AZD4694 Precursor
HY-111052R-01AZD7325 (Standard)

Alternative Products

CatalogName
T63236AZD4625
A24541-1AZD4625 1mg
A24541-5AZD4625 5mg
A24541-10AZD4625 10mg
A24541-50AZD4625 50mg

Popular Products